Sintilimab plus bevacizumab biosimilar IB1305 plus chemotherapy for patients with EGFR-mutated NSCLC showed longer median PFS than the sintilimab plus chemotherapy and chemotherapy alone groups (median PFS, 9.8, vs. 6.9, vs. 4.3 months) (27). Here, EGFR is linked to non-small cell lung carcinoma.